S.I.T. - Sordina IORT Technologies, registered in Rome with a factory in Aprilia, makes small mobile electron accelerators that deliver radiotherapy inside the operating room while a tumour bed is exposed. Its EIC project, LIACFLASH, added the ability to deliver FLASH radiotherapy, an ultra-high dose rate that in research "enables delivery of high radiation dose with significantly reduced associated radiocytotoxicity" to healthy tissue, according to CORDIS.
The European Innovation Council granted €2,499,963 towards a €3.57 million project from December 2022 to May 2025. The final report says SIT designed and validated "the first medical linear accelerator (LINAC) capable of delivering both conventional and FLASH dose-rate electron radiotherapy" for surgery, reached TRL 8, built an AI-assisted planning unit and did pre-compliance testing against safety standards. It launched a contest to lend a system to a European clinic and said talks with strategic partners had begun "although formal agreements are still under evaluation". At ESTRO 2026 SIT described FLASH as "ongoing" development alongside its conventional LIAC HWL machine, according to its announcement.
Company file
- Legal entity
- S.I.T. - Sordina IORT Technologies S.p.A., registered office Rome
- Factory
- Aprilia (Latina)
- CEO
- Renato Cervo
- Products
- LIAC HWL (IOeRT), ElectronFlash (research), LIACFLASH
- Research partners
- Institut Curie, AtOMKI, University of Catania
- EIC project
- 1 Dec 2022 to 31 May 2025
- EIC funding
- Grant first
Where SIT Stands Now
SIT's recent news concerns its established machines and research platforms: a first intraoperative procedure with LIAC HWL at a hospital in Elche, Spain, in March 2026, an ElectronFlash system chosen by the University of Catania for glioblastoma research, and a research agreement with AtOMKI. In March 2026 its LIAC FLASH GT project was admitted for funding by the Italian business ministry's Sustainable Growth Fund, according to the company. SIT's ESTRO 2026 materials name a "CHC FlashPrime" platform for ultra-high dose rates as the next step towards clinical FLASH.
"Initial conversations with potential strategic partners were initiated, and early co-investment interest has been registered, although formal agreements are still under evaluation."
S.I.T. - Sordina IORT Technologies, final report to the EICThe Technology: Radiation in a Flash
FLASH radiotherapy delivers a dose at rates far above conventional treatment; the project says this widens the therapeutic window by harming healthy tissue less while still killing tumour cells. SIT has worked with Institut Curie since 2019, building the ElectronFlash research platform at Curie's Orsay site for in vitro and preclinical studies. LIACFLASH is meant to bring this into the operating room, and also to treat superficial tumours through the skin, without shielding the room.
What the EIC Project Promised, and What CORDIS Shows
The project promised a LIACFLASH system for cancer treatment, and the report documents a validated TRL 8 machine with planning software and three new patent applications. Moving it to patients requires certification and clinical trials, neither of which is reported as done. CORDIS still lists the project as signed.
- FLASH-capable IOeRT linacDeliveredTRL 8.
- AI planning unitDeliveredPer final report.
- Regulatory compliancePre-complianceNo certification reported.
- Clinical useNot yetNo FLASH patients.
The Money
SIT has not published revenue figures, and its Italian filings are not freely available online. The report says co-investment interest was registered but no agreement was reached by the end of the project. No EIC Fund investment has been announced; the award was grant first.
What Cannot Be Checked
Questions for the EIC
When LIACFLASH will be certified, which clinic won the loan system, whether a strategic partner signed and SIT's revenue are not public.
Why Europe Should Care
The report says about two in three cancer patients receive radiotherapy. SIT is a European manufacturer of the accelerators that could deliver it. The EIC paid for the machine; the clinical proof is still ahead.
What the project promised
An intraoperative radiotherapy system able to deliver both conventional and FLASH doses for cancer treatment.
What the record shows
A TRL 8 machine, patents and papers, and FLASH still described as under development in 2026.
The Verdict
Machine ready, medicine not
SIT built the FLASH-capable accelerator the EIC funded. Until it is certified and tested in patients, the promise of gentler, stronger radiotherapy remains a research result.
SIT and the EIC have not been asked for comment for this article. It is based entirely on public records and published statements, linked throughout.
